SymBio Pharmaceuticals Limited Logo

SymBio Pharmaceuticals Limited

Develops and commercializes drugs for oncology, hematology, and rare diseases.

4582 | T

Overview

Corporate Details

ISIN(s):
JP3383050006
LEI:
Country:
Japan
Address:
港区虎ノ門四丁目1番28号

Description

SymBio Pharmaceuticals Limited is a specialty pharmaceutical company focused on the development and commercialization of new drug candidates. The company's business model involves acquiring development and marketing rights for promising pharmaceuticals from other bio-ventures and pharmaceutical firms to address unmet medical needs. Its core therapeutic areas include oncology, hematology, and rare diseases. A key product in its portfolio is bendamustine hydrochloride (Treakisym), an agent used in the treatment of hematologic cancers such as low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. SymBio aims to deliver innovative treatments to patients by advancing its pipeline of specialized drugs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-08-05 02:11
確認書
Japanese ZIP 9.0 KB
2025-08-04 09:05
訂正有価証券届出書(参照方式)
Japanese ZIP 281.2 KB
2025-08-04 09:04
半期報告書-第21期(2025/01/01-2025/12/31)
Japanese ZIP 356.9 KB
2025-07-31 08:37
訂正有価証券届出書(参照方式)
Japanese ZIP 276.5 KB
2025-07-22 09:24
有価証券届出書(参照方式)
Japanese ZIP 524.8 KB
2025-04-21 03:23
訂正臨時報告書
Japanese ZIP 36.1 KB
2025-04-18 09:38
訂正臨時報告書
Japanese ZIP 40.4 KB
2025-03-26 05:29
訂正有価証券届出書(参照方式)
Japanese ZIP 207.2 KB
2025-03-26 05:04
臨時報告書
Japanese ZIP 26.2 KB
2025-03-25 07:35
臨時報告書
Japanese ZIP 44.1 KB
2025-03-25 07:34
訂正有価証券届出書(参照方式)
Japanese ZIP 312.0 KB
2025-03-25 07:32
内部統制報告書-第20期(2024/01/01-2024/12/31)
Japanese ZIP 23.9 KB
2025-03-25 07:31
確認書
Japanese ZIP 9.0 KB
2025-03-25 07:30
有価証券報告書-第20期(2024/01/01-2024/12/31)
Japanese ZIP 1.9 MB
2025-02-20 08:20
訂正有価証券届出書(参照方式)
Japanese ZIP 241.9 KB

Automate Your Workflow. Get a real-time feed of all SymBio Pharmaceuticals Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SymBio Pharmaceuticals Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SymBio Pharmaceuticals Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ABEONA THERAPEUTICS INC. Logo
A clinical-stage biopharma developing cell and gene therapies for rare diseases.
United States of America
ABEO
ABINGDON HEALTH PLC Logo
A CDMO specializing in lateral flow assays, offering development to manufacturing services.
United Kingdom
ABDX
ABIONYX Pharma Logo
Develops biotherapies and drug delivery vectors using apolipoprotein A-I.
France
ABNX
ABIVAX Logo
Clinical-stage biotech developing therapeutics for chronic inflammatory diseases.
France
ABVX
Abivax S.A. Logo
Clinical-stage biotech developing miRNA therapeutics for inflammatory diseases.
United States of America
ABVX
ABL Diagnostics Logo
Develops molecular diagnostic solutions for managing infectious diseases.
France
ABLD
Abliva Logo
Biopharmaceutical company developing medicines for primary mitochondrial diseases.
Sweden
ABLI
AB Science Logo
Researches and develops protein kinase inhibitors for human and veterinary medicine.
France
AB
ABVC BIOPHARMA, INC. Logo
Develops botanical drugs and medical devices for oncology, ophthalmology, and CNS.
United States of America
ABVC
ACADIA PHARMACEUTICALS INC Logo
Biopharmaceutical company developing medicines for CNS disorders and rare diseases.
United States of America
ACAD

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.